Redeye comments on Spago Nanomedical announcing the outcome of its rights issue, sporting a subscription rate of some 94.6%. We are encouraged by the company securing needed capital to continue clinical development of its pipeline projects. The subscription price was slightly lower than we estimated in our financial projections, and we adjust our valuation slightly.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se